ArticleJournal of molecular histology2025
SOX4 promotes triple-negative breast cancer progression by promoting SRPX2 transcription to regulate AKR1C1.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Triple-negative breast cancer (TNBC) is a specific subtype of breast cancer that poses a serious threat to women's health. The aldo-keto reductase type 1 C (AKR1C) family serves as a crucial ferroptosis defense system, catalyzing the conversion of aldehydes and ketones into their corresponding alcohols. SRY-Box4 (SOX4), a transcription factor of the SOX (sry-related HMG-box) family, is important in regulating tumor progression. This study aims to investigate the mechanism through which AKR1C1 mediates the growth, invasion, and ferroptosis of triple-negative breast cancer cells. SRPX2 was highly expressed in TNBC tissues and cells and was detrimental to patient prognosis. SRPX2 knockdown inhibited TNBC cell viability, invasion, and Stemness of tumor while promoting TNBC cell apoptosis and ferroptosis. SOX4 could bind to SRPX2 and was highly expressed in TNBC tissues and cells, down-regulation of SOX4 could inhibit the expression of SRPX2. Silencing SRPX2 inhibited the expression of AKR1C1. Up-regulating AKR1C1 reversed the inhibitory effect of SRPX2 knockdown on cell viability, invasion, and sphere formation abilities, and also reversed the promotive effect on apoptosis in TNBC cells. In vivo, SRPX2 knockdown suppressed tumor growth and expression of Ki67 and AKR1C1 via down-regulated AKR1C1. SOX4 facilitates triple-negative breast cancer progression via promoting SRPX2 transcription to regulate AKR1C. This study is expected to explore potential therapeutic targets and strategies for the treatment of TNBC.
Indexed as
Identifiers
40663167What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.